Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05215847 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
A Phase 2 study, sponsored by Aardvark Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05215847 is a Phase 2 study that has completed, run by Aardvark Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT05215847, a Phase 2 study, has completed, sponsored by Aardvark Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).
Interventions
- DRUG ARD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2023-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05215847
The ClinicalTrials.gov registry entry for NCT05215847 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aardvark Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARD-101 is the first listed.
NCT05215847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05215847 about?
NCT05215847 is a clinical study titled "Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery". The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).
What is the current status of trial NCT05215847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-03-01. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT05215847?
The interventions under investigation include: ARD-101 (DRUG).
Who is sponsoring clinical trial NCT05215847?
This trial is sponsored by Aardvark Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.